Central Nervous System - Refresher 2022

The course reviews the current clinical management of the most common malignant and benign adult CNS tumors. This review is be followed by an overview of the current clinical practice in the treatment of brain metastases. The speaker reviews the evolving role of stereotactic radiosurgery and whole brain radiotherapy in combination with novel therapeutic agents in the treatment of brain metastases. The presenter discusses in depth the roles of surgery, radiotherapy, and chemotherapy in the management of each of these tumors.

Significant recent progress has been made in the management of CNS tumors, with an emphasis on new molecular prognostic and predictive biomarkers that allow for appropriate treatment selection. Recent updates of the 5th edition WHO Classification of CNS tumors in 2021 include new tumor types that will be summarized. The importance of neuroimaging in helping clinicians improve diagnosis, treatment and response assessment for CNS tumors will be emphasized. This session highlights the need for a multi-disciplinary treatment approach in the management of CNS tumors.

This activity is available from May 9, 2022, through 11:59 p.m. Eastern time on May 8, 2025.

This activity was originally recorded at ASTRO’s virtual 2022 ASTRO Annual Refresher Course, March 25-27, 2022.

Target Audience

The activity is designed to meet the interests of radiation oncologists and radiation oncology residents, medical oncologists, surgeons, physicists, nurses, radiation therapists, patologists, radiation therapists and dosimetrists.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Discuss the role of each modality including surgery, radiotherapy, and chemotherapy in managing the major malignant and benign adult primary CNS tumors.
  • Describe the new updates of the 5th edition of the WHO Classification of Tumors of the CNS 2021 substantial heterogeneity that exists within these tumor types and understand the prognostic and predictive variables that allow for the selection of the appropriate therapy.
  • Discuss key imaging modalities and features to differentiate recurrent tumor and treatment effect.
Course summary
Available credit: 
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
  • 1.50 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

Course opens: 
05/09/2022
Course expires: 
05/08/2025
Cost:
$105.00
Rating: 
0

Christina Tsien, MD is employed by Johns Hopkins University and receives compensation from Varian, Merck, BlueEarth, Novocure and Tocagen.

The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.

All relevant relationships have been mitigated.

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
  • 1.50 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.

Price

Cost:
$105.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  • Nonmember: $105
  • Member: $55

Policies:
No refunds, extensions, or substitutions will be made for participants, including those who for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.